Trials / Completed
CompletedNCT04831996
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.
A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Parsaclisib in Participants With Normal Renal Function and Participants With Renal Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years – 82 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal renal function and participants with renal impairment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | parsaclisib | parsaclisib will be administered orally after 8 hours of fasting. |
Timeline
- Start date
- 2021-05-04
- Primary completion
- 2022-07-08
- Completion
- 2022-07-08
- First posted
- 2021-04-05
- Last updated
- 2022-08-17
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04831996. Inclusion in this directory is not an endorsement.